Deoxinate
Deoxinate: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. Drug interactions
- 12. Analogs
- 13. Terms and conditions of storage
- 14. Terms of dispensing from pharmacies
- 15. Reviews
- 16. Price in pharmacies
Latin name: Desoxynatum
ATX code: L03AX
Active ingredient: sodium deoxyribonucleate (Sodium deoxyribonucleate)
Producer: Pharmzashchita NPC, FSUE (Russia)
Description and photo update: 2019-11-07
Deoxinate is an immunomodulatory agent.
Release form and composition
Dosage forms of Deoxinate:
- solution for intramuscular (i / m) and subcutaneous (s / c) administration: transparent colorless liquid (5 ml in a neutral glass ampoule, in a blister strip made of polyvinyl chloride film 5 ampoules, in a cardboard box 2 packs);
- solution for local and external use: transparent colorless liquid (50 ml in a bottle for infusion solutions, hermetically sealed with a rubber stopper with an aluminum or aluminum-plastic cap, 1 bottle in a cardboard box).
Each pack also contains instructions for the use of Deoxinate.
1 ml of solution for intramuscular and subcutaneous administration contains:
- active substance: deoxinate (sodium deoxyribonucleate) - 5 mg;
- additional components: sodium chloride, water for injection.
1 ml of solution for local and external use contains:
- active substance: deoxinate (sodium deoxyribonucleate) - 2.5 mg;
- additional components: sodium chloride, methyl parahydroxybenzoate (nipagin), water for injection.
Pharmacological properties
Pharmacodynamics
Deoxinate demonstrates an immunomodulatory effect at the cellular and humoral levels. The tool helps to activate antifungal, antiviral and antimicrobial immunity. Shows a radioprotective effect, stimulates regeneration - accelerates the healing of wounds and ulcerative necrotic lesions of the skin and mucous membranes, activates the formation of granulations and epithelium. When using the solution for local and external use in the form of applications, dressings and rinsing, an analgesic effect is also noted, the severity of the inflammatory reaction decreases. The active substance regulates hematopoiesis - it helps to normalize the number of leukocytes, phagocytes, granulocytes, platelets, lymphocytes. Deoxinate leads to an increase in the engraftment of autografts in the treatment of superficial burns,as well as allografts for plastic deformities and defects of the maxillofacial region.
According to experimental data, Deoxinat demonstrates a therapeutic effect against the background of acute radiation sickness of the II – III degree of severity in hypo- and aplastic conditions of the blood system caused by radiation or polychemotherapy. After a single intramuscular injection of the drug, there is a rapid leuko-stimulating effect in cancer patients with grade III and life-threatening grade IV leukopenia caused by the use of polychemotherapy or combined polychemotherapy. First of all, in this case, an increase in the level of content in the peripheral blood by 5-7 times of the absolute number of granulocytes is recorded. At the same time, due to the activity of the drug, there is an increase in the absolute number of lymphocytes and normalization of the level of platelet concentration in the peripheral blood in thrombocytopenia of I – IV degrees of the same genesis.
Deoxinate does not affect tumor growth and the therapeutic effect of cytostatics or chemoradiotherapy, does not lead to immediate or delayed side effects, does not have mutagenic, carcinogenic or allergic properties.
As a result of a single intramuscular injection of an immunomodulatory agent within the first 24 hours after the total exposure of the body to ionizing radiation, the clinical course of radiation sickness is facilitated in the experiment, the onset and rate of recovery of stem cells in the bone marrow, as well as lymphoid, myeloid and platelet hematopoiesis, is accelerated.
Thanks to the action of the drug, the likelihood of favorable outcomes of radiation sickness increases. The positive therapeutic effect of Deoxinat is observed in acute pharyngeal syndrome, in thermal burns, primary and late radiation ulcers, and in complications associated with cytostatic therapy.
Pharmacokinetics
Deoxinate is rapidly absorbed and distributed in tissues and organs, including with the participation of the endolymphatic pathway. Demonstrates high affinity for the organs of the hematopoietic system, actively participates in cell metabolism, having the ability to integrate into cellular structures. In the phase of increased flow of funds into the blood, a redistribution occurs between the blood corpuscles and plasma in parallel with metabolic transformation and excretion.
After one injection, all pharmacokinetic curves that describe the change in the concentration of the drug in the studied tissues and organs are characterized by rapid phases of increase and decrease in the content in the time interval of 5-24 hours.
The half-life (T ½) with IM administration of Deoxinate is 72.3 hours. The drug, intensively distributed throughout the body, with daily course use accumulates in organs and tissues: in maximum doses - in the lymph nodes, bone marrow, spleen, thymus, in smaller doses - in the brain, stomach, liver, small and large intestines.
The highest concentration in the bone marrow is recorded 5 hours after the administration of Deoxinate. The agent passes through the blood-brain barrier, the maximum level of concentration in the brain is noted after 30 minutes.
The drug is biotransformed in the body. The end products of metabolism are beta-alanine, xanthine, hypoxanthine, propionic, acetic and uric acids, which are eliminated from the gastrointestinal tract (GIT). From the body (in the form of metabolites) it is excreted by the kidneys in a biexponential relationship and, in part, through the gastrointestinal tract.
Indications for use
Solution for intramuscular and subcutaneous administration
- severe myelodepression (leuko- and thrombocytopenia) in cancer patients, caused by cytostatics (mono- or polychemotherapy) or combined chemoradiation therapy (treatment);
- severe leuko- and thrombocytopenia, detected during the previous cycle of chemo- or chemoradiation therapy, the presence of thrombocytopenic (less than 150x10 9 / l) and leukopenic (less than 3.5x10 9 / l) background before the start of specific therapy - for prophylaxis, before the start of the chemotherapy cycle or chemoradiation, especially repeated, during its course or after completion; with leukopenia and / or thrombocytopenia that developed during the course of chemotherapy (chemoradiation therapy) or after its completion; the indication for the use of the drug is a decrease in the level of leukocytes in the peripheral blood to 2x10 9 / l, platelets 100x10 9 / l and less.
According to experimental data, Deoxinat is also indicated for patients who have been exposed to acute exposure to ionizing radiation in doses leading to the development of radiation sickness of II – III severity.
Solution for local and external use
- acute radiation pharyngeal syndrome;
- primary, late radiation ulcers and thermal burns of the skin of the II – III degree of severity;
- trophic ulcers;
- decubital ulcers in the oral cavity and on the skin;
- violation of the integrity of the mucous membrane of the nasal cavity, mouth, rectum, vagina;
- complications associated with cytostatic therapy: gingivitis, pharyngoesophagitis, uvulitis, stomatitis, enterocolitis, paraproctitis, vulvovaginitis;
- the period of engraftment of grafts, preparation of tissues for auto- or allotransplantation.
Contraindications
A contraindication to the use of Deoxinat is an individual intolerance to any of its components.
In addition, the solution for local and external use is not recommended for use in pregnant and breastfeeding women.
With caution and only after consulting a doctor and a thorough assessment of the expected benefits of therapy for the mother and the possible threat to the health of the fetus, a solution for intramuscular and subcutaneous administration can be used during pregnancy. During breastfeeding, this form of the drug is allowed to be used strictly according to the doctor's prescription.
Deoxinate, instructions for use: method and dosage
Solution for intramuscular and subcutaneous administration
A solution of deoxinate in ampoules is administered i / m and s / c.
Adults and children (regardless of age) are prescribed single injections of the drug at a dose of 75 mg deoxinate (15 ml of solution). Repeated administration of the solution is allowed in cancer patients during the implementation of the next cycles of chemotherapy, radiation or chemoradiation treatment. Before use, the medicine stored in the refrigerator should be warmed to body temperature.
In the treatment of acute radiation sickness, Deoxinat is recommended to be used no later than 24 hours after irradiation.
Solution for local and external use
The drug is prescribed for adults and children from the first day of life.
Recommended method of application and dosage regimen of deoxinate, taking into account the localization of the process:
- skin lesions: externally in the form of application dressings soaked in a solution of the drug; change 3-4 times a day;
- lesions of the oral mucosa: topically in the form of rinsing with a solution (followed by swallowing) 4 times a day at a dose of 5-15 ml;
- vaginal lesions: intravaginally in the form of a tampon moistened with the drug;
- rectal lesions: rectally in the form of an enema, dose - 20-50 ml.
The course of treatment is continued until the signs of the inflammatory process are permanently removed and until the marked epithelialization of the skin and mucous membranes - 4-10 days.
Side effects
In / m and subcutaneous administration of Deoxinat does not lead to complications. In some cases, 4-24 hours after injection, short-term (no more than 2-4 hours) hyperthermia from subfebrile values to 38.5 ° C may occur, usually without worsening the patient's condition (chills, etc.) and does not require correction. In the case of forced administration of the solution, a short soreness at the injection site is possible, which does not require drug therapy.
When used topically, the immunomodulatory agent does not cause the development of undesirable effects.
If any of the above adverse reactions are aggravated, or any other disorders appear against the background of the use of Deoxinate, you should consult your doctor.
Overdose
Cases of drug overdose with local and external use have not been recorded to date. With intramuscular and subcutaneous administration, there were no negative effects against the background of an overdose.
special instructions
Intravenous administration of Deoxinate is not allowed.
With local and external use, the drug is ineffective against the background of extremely severe forms of lesions, extensive deep necrosis of IV degree of severity.
Influence on the ability to drive vehicles and complex mechanisms
There is no information on the negative effect of Deoxinat on the ability to drive vehicles and control other complex mechanisms.
Application during pregnancy and lactation
Solution for topical and external use is not recommended for pregnant and breastfeeding women.
A solution for intramuscular and subcutaneous administration during pregnancy can be used after consulting a doctor and a careful assessment of the expected benefits of therapy for the mother and the possible threat to the health of the fetus. During breastfeeding, this form of Deoxinate can be used strictly as directed by a doctor.
Pediatric use
Deoxinate can be used on the recommendation of the attending physician in children of any age according to the dosage regimen. The solution for local and external use can be used in children from the first day of life.
Drug interactions
Deoxinate, when administered intramuscularly and subcutaneously, potentiates the effect of cytostatics and antitumor antibiotics - anthracyclines.
When applied topically, the drug should not be combined with hydrogen peroxide solutions and fat-based ointments.
Analogs
Derinat, Panagen, Sodium deoxyribonucleate, Ridostin, etc. are analogs of Deoxinat.
Terms and conditions of storage
Store in a place protected from light, dry and out of reach of children, at a temperature of 2–8 ° C - solution for intramuscular and subcutaneous administration, 5–10 ° C - solution for local and external use.
The shelf life is 3 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Deoxinate
Reviews of Deoxinate on medical sites are rare. Many patients were satisfied with the therapy with the drug, mainly in the form of a solution for local and external use, and believe that it effectively has the declared therapeutic effect. It is noted that the drug has proven itself well in the treatment of stomatitis, recurrent furunculosis, trophic ulcers, sluggish granulating wounds, ENT pathologies, adhesions, chronic endometritis. Deoxinate solution in ampoules (for intramuscular and subcutaneous administration), according to patient reviews, has shown good results in the treatment of leukopenia. In the reviews of specialists, the drug is classified as an effective means of early treatment of radiation sickness.
However, there are also complaints from patients in which they indicate a low clinical effect of the immunomodulatory agent, as well as the development of side effects and pain at the site of its intramuscular injection. The absence of the drug in pharmacies is often noted.
The price of Deoxinat in pharmacies
The price of Deoxinate is unknown due to the fact that the drug is not currently available in the pharmacy network.
The price of an analogue of the drug, Derinat, a solution for local and external use of 0.25%, can be 208–327 rubles. per bottle of 10 ml. Derinat in the form of a solution for intramuscular injection of 15 mg / ml can be purchased for 1819-2187 rubles. per pack of 5 bottles of 5 ml.
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
